Continuation of Follow-up of DES-exposed Cohorts

继续对 DES 暴露组进行随访

• 批准号: 7933087
• 负责人: RAYMOND KAUFMAN
• 金额: $ 19.86万
• 依托单位: METHODIST HOSPITAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-30 至 2010-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7933087
• 关键词: Continuation; Follow; up; DES; exposed

1. Maintain contact with the DES-exposed individuals and unexposed controls already being followed in our follow-up program. This will be accomplished through two questionnaires sent to the participants during the period of the contract. 2. Continue to identify new third generation female offspring whose mothers were exposed in utero to DES and to examine these young women in a manner similar to the examination performed on their mothers in enrollment in the DESAD project. 3. Continue to evaluate the incidence of genital tract neoplasia in the exposed and unexposed cohorts as well as the mothers who took DES during their pregnancies. 4. Continue to estimate the incidence of intra epithelial neoplasia of the cervix and vagina. 5. Continue to evaluate the incidence of other benign and malignant neoplasms found in the DES-exposed cohorts. 6. Continue to assess the immunologic status of the subjects by determining the life-time occurrence of autoimmune diseases of exposed individuals as compared to the unexposed. 7. Continue to monitor the occurrence of medical disease in the exposed and unexposed cohorts and to make comparisons among them with published disease rates. 8. Obtain and confirm information of the diagnosis of all reported neoplasms in the DES and control cohorts.

1.与我们的随访计划中已经遵循的DES暴露个体和未暴露对照保持联系。这将通过在合同期间向参与者发送两份问卷来完成。 2.继续识别母亲在子宫内暴露于DES的新的第三代女性后代，并以与DESAD项目中对其母亲进行的检查相似的方式对这些年轻女性进行检查。 3.继续评价暴露和未暴露队列以及妊娠期间服用DES的母亲的生殖道肿瘤发生率。 4.继续估计宫颈和阴道上皮内瘤变的发生率。 5.继续评价DES暴露队列中发现的其他良性和恶性肿瘤的发生率。 6.通过确定暴露个体与未暴露个体相比自身免疫性疾病的终生发生率，继续评估受试者的免疫状态。 7.继续监测接触和未接触队列中医学疾病的发生率，并将其与公布的发病率进行比较。 8.获得并确认DES和对照队列中所有报告的肿瘤的诊断信息。